Testowanie połączenia cedyranibu i olaparybu w porównaniu z każdym lekiem stosowanym osobno lub inną chemioterapią w nawracającym platynoopornym raku jajnika
Randomizowane badanie fazy II/III dotyczące połączenia cedyranibu i olaparybu w porównaniu z cedyranibem lub samym olaparybem lub standardową chemioterapią u kobiet z nawracającym rakiem jajnika, jajowodu lub pierwotnym rakiem otrzewnej opornym na platynę lub opornym na leczenie (COCOS)
This randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned (recurrent) after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory). Cediranib maleate and olaparib may stop the growth of tumor cells by blocking enzymes needed for cell growth. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cediranib maleate and olaparib together may cause more damage to cancer cells when compared to either drug alone or standard chemotherapy.
Przegląd badań
Status
Warunki
- Nawracający rak jajowodu
- Nawracający rak jajnika
- Nawracający pierwotny rak otrzewnej
- Gruczolakorak endometrioidalny jajnika
- Rak surowiczo-śluzowy jajnika
- Niezróżnicowany rak jajnika
- Rak jasnokomórkowy jajnika
- Rak przejściowokomórkowy jajowodu
- Rak przejściowokomórkowy jajnika
- Rak jasnokomórkowy jajowodu
- Gruczolakorak endometrioidalny jajowodu
- Rak surowiczy jajowodu
- Niezróżnicowany rak jajowodu
- Gruczolakorak surowiczy jajnika
- Pierwotny gruczolakorak surowiczy otrzewnej
Szczegółowy opis
PRIMARY OBJECTIVES:
I. To assess the efficacy and identify (in)active arm(s) of the combination of cediranib maleate (cediranib) and olaparib, cediranib alone, olaparib alone, and physician's choice standard of care chemotherapy, as measured by progression-free survival (PFS) in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase II) II. To assess the efficacy of the combination of cediranib and olaparib, and cediranib monotherapy, as measured by overall survival (OS) and PFS, as compared to physician's choice standard of care chemotherapy in women with recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase III)
SECONDARY OBJECTIVES:
I. To assess the efficacy of the combination of cediranib and olaparib, cediranib alone, olaparib alone, and physician's choice standard of care chemotherapy, as measured by objective response rate (ORR: partial or complete response) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase II) II. To assess safety endpoints, as measured by frequency and severity of adverse events by Common Terminology Criteria for Adverse Events (CTCAE). (Phase II and Phase III) III. To assess the efficacy of the combination of cediranib and olaparib, and cediranib monotherapy, as measured by ORR as compared to physician's choice standard of care chemotherapy in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase III)
OBJECTIVES WITH INTEGRATED BIOMARKERS:
I. To assess correlation of homologous recombination deficiency (HRD) status, as assessed via BROCA-HR assay with response, as measured by PFS and ORR. (Phase II) II. To evaluate the prognostic and predictive role of circulating endothelial cells (CEC) on comparative effectiveness of targeted therapies and reference chemotherapy. (Phase II) III. To evaluate quality of life data compliance, as measured by the 9-item Disease Related Symptoms (DRS-9) subscale of the National Comprehensive Cancer Network (NCCN)-Functional Assessment of Cancer Therapy (FACT) Ovarian Symptom Index (NFOSI) for utilization and analysis in the Phase III study. (Phase II) IV. To assess correlation of HRD status, as assessed via BROCA-HR assay with response, as measured by OS, PFS and ORR. (Phase III) V. To evaluate the prognostic and predictive role of circulating endothelial cells (CEC) on comparative effectiveness of targeted therapies and reference chemotherapy. (Phase III) VI. To assess the effect on disease-related symptoms (DRS) as measured by the 9-item DRS-P subscale of the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18), of single agent cediranib and cediranib/olaparib combination, compared to standard chemotherapy, in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase III)
EXPLORATORY OBJECTIVES:
I. To assess exploratory biomarkers of potential HRD, including genomic scarring, BRCA1 methylation, BRCA1 protein expression, and mutations in NHEJ, and other genes that might modify HRD. (Phase II and Phase III) II. To evaluate the prognostic and predictive role of angiogenic biomarkers, as assessed by the Duke plasma angiome. (Phase II and Phase III) III. To assess the effect on secondary measures of quality of life, as assessed by the treatment side effects (TSE) and function/well-being (F/WB) subscales of the NFOSI-18, sensory neuropathy as measured by the FACT/GOG-Ntx-4, and health utility as measured by the EQ-5D, of single agent cediranib and cediranib/olaparib combination, compared to standard chemotherapy, in the setting of recurrent platinum-resistant or-refractory ovarian, primary peritoneal or fallopian tube cancer. (Phase III)
OUTLINE:
PHASE II: Patients are randomized to 1 of 4 treatment arms.
ARM I (REFERENCE REGIMEN): Patients undergo physician's choice of standard of care chemotherapy, comprising either paclitaxel intravenously (IV) over 60 minutes on days 1, 8, 15, and 22 every 28 days (Regimen I); pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 every 28 days (Regimen II); or topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15 every 28 days or days 1-5 every 21 days (Regimen III). Treatment continues in the absence of disease progression or unacceptable toxicity. No modification of the assigned regimens, such as additional drugs (gemcitabine, or bevacizumab) is allowed. Patients also undergo computed tomography (CT) and magnetic resonance imaging (MRI) throughout the study. (12/05/2016)
ARM II (CEDIRANIB MALEATE AND OLAPARIB): Patients receive cediranib maleate orally (PO) once daily (QD) and olaparib PO twice daily (BID). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.
ARM III (CEDIRANIB): Patients receive cediranib maleate PO daily continuously. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.
ARM IV (OLAPARIB): Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study. (In July 2018, the Data Monitoring Committee voted to exclude the olaparib alone regimen).
PHASE III: Patients are randomized to 1 of 3 treatment arms.
ARM I (REFERENCE REGIMEN): Patients undergo physician's choice standard of care chemotherapy as in Phase II Arm I. No modification of the assigned regimens, such as additional drugs (gemcitabine or bevacizumab) is allowed. Patients also undergo CT and MRI throughout the study. (12/05/2016)
ARM II (CEDIRANIB AND OLAPARIB): Patients receive cediranib maleate PO and olaparib PO as in Phase II Arm II. Patients also undergo CT and MRI throughout the study.
ARM III (SINGLE AGENT): Patients receive cediranib maleate PO as determined by the Phase II study. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for up to 3 years.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
- Faza 3
Kontakty i lokalizacje
Lokalizacje studiów
-
-
-
Osaka, Japonia, 589 8511
- Kindai University
-
Saitama, Japonia, 350-1298
- Saitama Medical University International Medical Center
-
Tokyo, Japonia, 104 0045
- National Cancer Center Hospital
-
-
Ehime
-
Tōon, Ehime, Japonia, 791-0295
- Ehime University Hospital
-
-
Hokkaido
-
Sapporo, Hokkaido, Japonia, 060-8648
- Hokkaido University Hospital
-
-
Kagoshima-ken
-
Kagoshima, Kagoshima-ken, Japonia, 890-8760
- Kagoshima City Hospital
-
-
Tokyo
-
Koto-ku, Tokyo, Japonia, 135-8550
- The Cancer Institute Hospital Of JFCR
-
-
-
-
Alberta
-
Calgary, Alberta, Kanada, T2N 5G2
- Arthur J E Child Comprehensive Cancer Centre
-
Edmonton, Alberta, Kanada, T6G 1Z2
- Cross Cancer Institute
-
-
Ontario
-
Barrie, Ontario, Kanada, L4M 6M2
- Royal Victoria Regional Health Centre
-
Hamilton, Ontario, Kanada, L8V 5C2
- Juravinski Cancer Centre at Hamilton Health Sciences
-
Kingston, Ontario, Kanada, K7L 2V7
- Kingston Health Sciences Centre
-
London, Ontario, Kanada, N6A 4L6
- London Regional Cancer Program
-
Sault Ste. Marie, Ontario, Kanada, P6B 0A8
- Algoma District Cancer Program Sault Area Hospital
-
Toronto, Ontario, Kanada, M5G 2M9
- University Health Network-Princess Margaret Hospital
-
Toronto, Ontario, Kanada, M4N 3M5
- Odette Cancer Centre- Sunnybrook Health Sciences Centre
-
-
Quebec
-
Montreal, Quebec, Kanada, H3T 1E2
- Jewish General Hospital
-
Montreal, Quebec, Kanada, H2X 3E4
- CHUM - Centre Hospitalier de l'Universite de Montreal
-
Montreal, Quebec, Kanada, H1T 2M4
- CIUSSSEMTL-Hopital Maisonneuve-Rosemont
-
Québec, Quebec, Kanada, G1R 2J6
- CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)
-
-
-
-
-
Incheon, Korea Południowa, 405-760
- Gachon University Gil Hospital
-
Seoul, Korea Południowa, 05505
- Asan Medical Center
-
Seoul, Korea Południowa, 06273
- Gangnam Severance Hospital
-
Seoul, Korea Południowa, 134-727
- Kyung Hee University Hospital at Gangdong
-
Seoul, Korea Południowa, 139-706
- Korea Cancer Center Hospital
-
-
Daegu
-
Dalseo-gu, Daegu, Korea Południowa, 42601
- Keimyung University-Dongsan Medical Center
-
-
Kyeonggi-do
-
Seongnam, Kyeonggi-do, Korea Południowa, 463-707
- Seoul National University Bundang Hospital
-
-
-
-
-
San Juan, Portoryko, 00927
- Centro Comprensivo de Cancer de UPR
-
-
-
-
Alabama
-
Birmingham, Alabama, Stany Zjednoczone, 35233
- University of Alabama at Birmingham Cancer Center
-
-
Alaska
-
Anchorage, Alaska, Stany Zjednoczone, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Stany Zjednoczone, 99508
- Providence Alaska Medical Center
-
-
Arkansas
-
Little Rock, Arkansas, Stany Zjednoczone, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Auburn, California, Stany Zjednoczone, 95602
- Sutter Auburn Faith Hospital
-
Berkeley, California, Stany Zjednoczone, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Carmichael, California, Stany Zjednoczone, 95608
- Mercy San Juan Medical Center
-
Elk Grove, California, Stany Zjednoczone, 95758
- Mercy Cancer Center - Elk Grove
-
Greenbrae, California, Stany Zjednoczone, 94904
- Marin Cancer Care Inc
-
La Jolla, California, Stany Zjednoczone, 92093
- UC San Diego Moores Cancer Center
-
Mountain View, California, Stany Zjednoczone, 94040
- Palo Alto Medical Foundation-Camino Division
-
Mountain View, California, Stany Zjednoczone, 94040
- Palo Alto Medical Foundation-Gynecologic Oncology
-
Oakland, California, Stany Zjednoczone, 94611
- Kaiser Permanente-Oakland
-
Palo Alto, California, Stany Zjednoczone, 94301
- Palo Alto Medical Foundation Health Care
-
Rocklin, California, Stany Zjednoczone, 95765
- Mercy Cancer Center - Rocklin
-
Roseville, California, Stany Zjednoczone, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Stany Zjednoczone, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, Stany Zjednoczone, 95817
- University of California Davis Comprehensive Cancer Center
-
Sacramento, California, Stany Zjednoczone, 95814
- Kaiser Permanente Downtown Commons
-
Sacramento, California, Stany Zjednoczone, 95825
- Kaiser Permanente Sacramento Medical Center
-
Sacramento, California, Stany Zjednoczone, 95816
- Mercy Cancer Center - Sacramento
-
San Francisco, California, Stany Zjednoczone, 94115
- Kaiser Permanente-San Francisco
-
San Francisco, California, Stany Zjednoczone, 94158
- UCSF Medical Center-Mission Bay
-
San Francisco, California, Stany Zjednoczone, 94115
- California Pacific Medical Center-Pacific Campus
-
San Luis Obispo, California, Stany Zjednoczone, 93401
- Pacific Central Coast Health Center-San Luis Obispo
-
Santa Clara, California, Stany Zjednoczone, 95051
- Kaiser Permanente Medical Center - Santa Clara
-
Santa Cruz, California, Stany Zjednoczone, 95065
- Palo Alto Medical Foundation-Santa Cruz
-
Santa Rosa, California, Stany Zjednoczone, 95403
- Sutter Pacific Medical Foundation
-
Sunnyvale, California, Stany Zjednoczone, 94086
- Palo Alto Medical Foundation-Sunnyvale
-
Vallejo, California, Stany Zjednoczone, 94589
- Kaiser Permanente-Vallejo
-
Walnut Creek, California, Stany Zjednoczone, 94596
- Kaiser Permanente-Walnut Creek
-
Woodland, California, Stany Zjednoczone, 95695
- Woodland Memorial Hospital
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80045
- UCHealth University of Colorado Hospital
-
Colorado Springs, Colorado, Stany Zjednoczone, 80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs, Colorado, Stany Zjednoczone, 80909
- UCHealth Memorial Hospital Central
-
Denver, Colorado, Stany Zjednoczone, 80205
- Kaiser Permanente-Franklin
-
Denver, Colorado, Stany Zjednoczone, 80220
- Rocky Mountain Cancer Centers-Rose
-
Fort Collins, Colorado, Stany Zjednoczone, 80524
- Poudre Valley Hospital
-
Highlands Ranch, Colorado, Stany Zjednoczone, 80129
- UCHealth Highlands Ranch Hospital
-
Lafayette, Colorado, Stany Zjednoczone, 80026
- Kaiser Permanente-Rock Creek
-
Lone Tree, Colorado, Stany Zjednoczone, 80124
- Kaiser Permanente-Lone Tree
-
-
Connecticut
-
Danbury, Connecticut, Stany Zjednoczone, 06810
- Danbury Hospital
-
Fairfield, Connecticut, Stany Zjednoczone, 06824
- Smilow Cancer Hospital Care Center-Fairfield
-
Hartford, Connecticut, Stany Zjednoczone, 06105
- Smilow Cancer Hospital Care Center at Saint Francis
-
Hartford, Connecticut, Stany Zjednoczone, 06102
- Hartford Hospital
-
Middletown, Connecticut, Stany Zjednoczone, 06457
- Middlesex Hospital
-
New Britain, Connecticut, Stany Zjednoczone, 06050
- The Hospital of Central Connecticut
-
New Haven, Connecticut, Stany Zjednoczone, 06520
- Yale University
-
Norwalk, Connecticut, Stany Zjednoczone, 06856
- Norwalk Hospital
-
Trumbull, Connecticut, Stany Zjednoczone, 06611
- Smilow Cancer Hospital Care Center-Trumbull
-
-
Delaware
-
Newark, Delaware, Stany Zjednoczone, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Stany Zjednoczone, 19713
- Medical Oncology Hematology Consultants PA
-
Newark, Delaware, Stany Zjednoczone, 19718
- Christiana Care Health System-Christiana Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stany Zjednoczone, 20016
- Sibley Memorial Hospital
-
-
Florida
-
Gainesville, Florida, Stany Zjednoczone, 32610
- UF Health Cancer Institute - Gainesville
-
Miami Beach, Florida, Stany Zjednoczone, 33140
- Mount Sinai Medical Center
-
Orlando, Florida, Stany Zjednoczone, 32806
- Orlando Health Cancer Institute
-
Sarasota, Florida, Stany Zjednoczone, 34239
- Sarasota Memorial Hospital
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Stany Zjednoczone, 30322
- Emory University Hospital/Winship Cancer Institute
-
Atlanta, Georgia, Stany Zjednoczone, 30309
- Piedmont Hospital
-
Atlanta, Georgia, Stany Zjednoczone, 30342
- Northside Hospital
-
Augusta, Georgia, Stany Zjednoczone, 30912
- Augusta University Medical Center
-
Austell, Georgia, Stany Zjednoczone, 30106
- WellStar Cobb Hospital
-
Marietta, Georgia, Stany Zjednoczone, 30060
- Wellstar Kennestone Hospital
-
Marietta, Georgia, Stany Zjednoczone, 30060
- WellStar Health System Inc
-
Roswell, Georgia, Stany Zjednoczone, 30076
- WellStar North Fulton Hospital
-
Savannah, Georgia, Stany Zjednoczone, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
Savannah, Georgia, Stany Zjednoczone, 31404
- Memorial Health University Medical Center
-
Smyrna, Georgia, Stany Zjednoczone, 30080
- WellStar Vinings Health Park
-
-
Hawaii
-
Honolulu, Hawaii, Stany Zjednoczone, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Stany Zjednoczone, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, Stany Zjednoczone, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Stany Zjednoczone, 83712
- Saint Luke's Cancer Institute - Boise
-
Fruitland, Idaho, Stany Zjednoczone, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Stany Zjednoczone, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Stany Zjednoczone, 83687
- Saint Luke's Cancer Institute - Nampa
-
-
Illinois
-
Aurora, Illinois, Stany Zjednoczone, 60504
- Rush-Copley Medical Center
-
Bloomington, Illinois, Stany Zjednoczone, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Stany Zjednoczone, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, Stany Zjednoczone, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Stany Zjednoczone, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Stany Zjednoczone, 60611
- Northwestern University
-
Chicago, Illinois, Stany Zjednoczone, 60612
- John H Stroger Jr Hospital of Cook County
-
Chicago, Illinois, Stany Zjednoczone, 60657
- UChicago Medicine Comprehensive Cancer Center - Saint Joseph Hospital
-
Chicago, Illinois, Stany Zjednoczone, 60612
- Rush MD Anderson Cancer Center
-
Decatur, Illinois, Stany Zjednoczone, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Stany Zjednoczone, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Stany Zjednoczone, 62401
- Crossroads Cancer Center
-
Eureka, Illinois, Stany Zjednoczone, 61530
- Illinois CancerCare-Eureka
-
Evanston, Illinois, Stany Zjednoczone, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, Stany Zjednoczone, 61401
- Illinois CancerCare-Galesburg
-
Geneva, Illinois, Stany Zjednoczone, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Stany Zjednoczone, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, Stany Zjednoczone, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Hinsdale, Illinois, Stany Zjednoczone, 60521
- Sudarshan K Sharma MD Limited-Gynecologic Oncology
-
Kewanee, Illinois, Stany Zjednoczone, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Stany Zjednoczone, 61455
- Illinois CancerCare-Macomb
-
O'Fallon, Illinois, Stany Zjednoczone, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Stany Zjednoczone, 61350
- Illinois CancerCare-Ottawa Clinic
-
Pekin, Illinois, Stany Zjednoczone, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Stany Zjednoczone, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Stany Zjednoczone, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, Stany Zjednoczone, 61356
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Stany Zjednoczone, 62702
- Springfield Clinic
-
Springfield, Illinois, Stany Zjednoczone, 62781
- Springfield Memorial Hospital
-
Warrenville, Illinois, Stany Zjednoczone, 60555
- Northwestern Medicine Cancer Center Warrenville
-
Zion, Illinois, Stany Zjednoczone, 60099
- Midwestern Regional Medical Center
-
-
Indiana
-
Fort Wayne, Indiana, Stany Zjednoczone, 46845
- Parkview Regional Medical Center
-
Indianapolis, Indiana, Stany Zjednoczone, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, Stany Zjednoczone, 46260
- Ascension Saint Vincent Indianapolis Hospital
-
Richmond, Indiana, Stany Zjednoczone, 47374
- Reid Health
-
South Bend, Indiana, Stany Zjednoczone, 46601
- Memorial Hospital of South Bend
-
-
Iowa
-
Clive, Iowa, Stany Zjednoczone, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Stany Zjednoczone, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Des Moines, Iowa, Stany Zjednoczone, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Stany Zjednoczone, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Stany Zjednoczone, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Stany Zjednoczone, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Iowa City, Iowa, Stany Zjednoczone, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
Sioux City, Iowa, Stany Zjednoczone, 51101
- Siouxland Regional Cancer Center
-
West Des Moines, Iowa, Stany Zjednoczone, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Wichita, Kansas, Stany Zjednoczone, 67214
- Ascension Via Christi Hospitals Wichita
-
Wichita, Kansas, Stany Zjednoczone, 67208
- Associates In Womens Health
-
-
Kentucky
-
Edgewood, Kentucky, Stany Zjednoczone, 41017
- Saint Elizabeth Healthcare Edgewood
-
Lexington, Kentucky, Stany Zjednoczone, 40536
- University of Kentucky/Markey Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Stany Zjednoczone, 70809
- Mary Bird Perkins Cancer Center
-
Baton Rouge, Louisiana, Stany Zjednoczone, 70809
- Hematology/Oncology Clinic PLLC
-
Baton Rouge, Louisiana, Stany Zjednoczone, 70817
- Woman's Hospital
-
Covington, Louisiana, Stany Zjednoczone, 70433
- Women's Cancer Care-Covington
-
New Orleans, Louisiana, Stany Zjednoczone, 70121
- Ochsner Medical Center Jefferson
-
-
Maine
-
Bangor, Maine, Stany Zjednoczone, 04401
- Eastern Maine Medical Center
-
Brewer, Maine, Stany Zjednoczone, 04412
- Lafayette Family Cancer Center-EMMC
-
Scarborough, Maine, Stany Zjednoczone, 04074
- MaineHealth Maine Medical Center- Scarborough
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21237
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute
-
Baltimore, Maryland, Stany Zjednoczone, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Stany Zjednoczone, 21204
- Greater Baltimore Medical Center
-
Bel Air, Maryland, Stany Zjednoczone, 21014
- UM Upper Chesapeake Medical Center
-
Bethesda, Maryland, Stany Zjednoczone, 20892
- National Institutes of Health Clinical Center
-
Ocean Pines, Maryland, Stany Zjednoczone, 21811
- TidalHealth Richard A Henson Cancer Institute
-
Salisbury, Maryland, Stany Zjednoczone, 21801
- TidalHealth Peninsula Regional
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Stany Zjednoczone, 02115
- Brigham and Women's Hospital
-
Worcester, Massachusetts, Stany Zjednoczone, 01605
- UMass Memorial Medical Center - Memorial Division
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48109
- University of Michigan Rogel Cancer Center
-
Ann Arbor, Michigan, Stany Zjednoczone, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brownstown, Michigan, Stany Zjednoczone, 48183
- Henry Ford Cancer Institute-Downriver
-
Clinton Township, Michigan, Stany Zjednoczone, 48038
- Henry Ford Macomb Hospital-Clinton Township
-
Detroit, Michigan, Stany Zjednoczone, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Stany Zjednoczone, 48201
- Wayne State University/Karmanos Cancer Institute
-
Escanaba, Michigan, Stany Zjednoczone, 49829
- OSF Saint Francis Hospital and Medical Group
-
Farmington Hills, Michigan, Stany Zjednoczone, 48334
- Weisberg Cancer Treatment Center
-
Grand Rapids, Michigan, Stany Zjednoczone, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Kalamazoo, Michigan, Stany Zjednoczone, 49007
- West Michigan Cancer Center
-
Lansing, Michigan, Stany Zjednoczone, 48912
- University of Michigan Health - Sparrow Lansing
-
Pontiac, Michigan, Stany Zjednoczone, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Traverse City, Michigan, Stany Zjednoczone, 49684
- Munson Medical Center
-
West Bloomfield, Michigan, Stany Zjednoczone, 48322
- Henry Ford West Bloomfield Hospital
-
-
Minnesota
-
Bemidji, Minnesota, Stany Zjednoczone, 56601
- Sanford Joe Lueken Cancer Center
-
Burnsville, Minnesota, Stany Zjednoczone, 55337
- Fairview Ridges Hospital
-
Coon Rapids, Minnesota, Stany Zjednoczone, 55433
- Mercy Hospital
-
Edina, Minnesota, Stany Zjednoczone, 55435
- Fairview Southdale Hospital
-
Mankato, Minnesota, Stany Zjednoczone, 56001
- Mayo Clinic Health Systems-Mankato
-
Maple Grove, Minnesota, Stany Zjednoczone, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, Stany Zjednoczone, 55109
- Saint John's Hospital - Healtheast
-
Minneapolis, Minnesota, Stany Zjednoczone, 55407
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, Stany Zjednoczone, 55455
- University of Minnesota/Masonic Cancer Center
-
Rochester, Minnesota, Stany Zjednoczone, 55905
- Mayo Clinic in Rochester
-
Saint Louis Park, Minnesota, Stany Zjednoczone, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Stany Zjednoczone, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Stany Zjednoczone, 55102
- United Hospital
-
Shakopee, Minnesota, Stany Zjednoczone, 55379
- Saint Francis Regional Medical Center
-
Woodbury, Minnesota, Stany Zjednoczone, 55125
- Minnesota Oncology Hematology PA-Woodbury
-
-
Mississippi
-
Jackson, Mississippi, Stany Zjednoczone, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Cape Girardeau, Missouri, Stany Zjednoczone, 63703
- Saint Francis Medical Center
-
Columbia, Missouri, Stany Zjednoczone, 65212
- MU Health - University Hospital/Ellis Fischel Cancer Center
-
Joplin, Missouri, Stany Zjednoczone, 64804
- Mercy Hospital Joplin
-
Springfield, Missouri, Stany Zjednoczone, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Stany Zjednoczone, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Stany Zjednoczone, 63110
- Barnes-Jewish Hospital
-
St Louis, Missouri, Stany Zjednoczone, 63110
- Washington University School of Medicine
-
-
Montana
-
Billings, Montana, Stany Zjednoczone, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Stany Zjednoczone, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Stany Zjednoczone, 59405
- Benefis Sletten Cancer Institute
-
-
Nebraska
-
Grand Island, Nebraska, Stany Zjednoczone, 68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
Kearney, Nebraska, Stany Zjednoczone, 68847
- CHI Health Good Samaritan
-
Omaha, Nebraska, Stany Zjednoczone, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Stany Zjednoczone, 68124
- Alegent Health Bergan Mercy Medical Center
-
Omaha, Nebraska, Stany Zjednoczone, 68130
- Alegent Health Lakeside Hospital
-
-
Nevada
-
Las Vegas, Nevada, Stany Zjednoczone, 89106
- Women's Cancer Center of Nevada
-
-
New Hampshire
-
Lebanon, New Hampshire, Stany Zjednoczone, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Nashua, New Hampshire, Stany Zjednoczone, 03063
- Dartmouth Cancer Center - Nashua
-
-
New Jersey
-
Camden, New Jersey, Stany Zjednoczone, 08103
- Cooper Hospital University Medical Center
-
Hackensack, New Jersey, Stany Zjednoczone, 07601
- Hackensack University Medical Center
-
Hamilton, New Jersey, Stany Zjednoczone, 08690
- The Cancer Institute of New Jersey Hamilton
-
Morristown, New Jersey, Stany Zjednoczone, 07960
- Morristown Medical Center
-
Neptune City, New Jersey, Stany Zjednoczone, 07753
- Jersey Shore Medical Center
-
New Brunswick, New Jersey, Stany Zjednoczone, 08903
- Rutgers Cancer Institute of New Jersey
-
Somerville, New Jersey, Stany Zjednoczone, 08876
- Robert Wood Johnson University Hospital Somerset
-
Summit, New Jersey, Stany Zjednoczone, 07902
- Overlook Hospital
-
Voorhees Township, New Jersey, Stany Zjednoczone, 08043
- MD Anderson Cancer Center at Cooper-Voorhees
-
-
New Mexico
-
Albuquerque, New Mexico, Stany Zjednoczone, 87106
- Southwest Gynecologic Oncology Associates Inc
-
Albuquerque, New Mexico, Stany Zjednoczone, 87106
- University of New Mexico Cancer Center
-
Las Cruces, New Mexico, Stany Zjednoczone, 88011
- Memorial Medical Center-Las Cruces
-
-
New York
-
Albany, New York, Stany Zjednoczone, 12208
- Women's Cancer Care Associates LLC
-
Brooklyn, New York, Stany Zjednoczone, 11203
- State University of New York Downstate Medical Center
-
Buffalo, New York, Stany Zjednoczone, 14263
- Roswell Park Cancer Institute
-
New York, New York, Stany Zjednoczone, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Stany Zjednoczone, 14642
- University of Rochester
-
Stony Brook, New York, Stany Zjednoczone, 11794
- Stony Brook University Medical Center
-
Syracuse, New York, Stany Zjednoczone, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Stany Zjednoczone, 10461
- Montefiore Medical Center-Einstein Campus
-
White Plains, New York, Stany Zjednoczone, 10601
- Dickstein Cancer Treatment Center
-
-
North Carolina
-
Asheville, North Carolina, Stany Zjednoczone, 28803
- AdventHealth Infusion Center Asheville
-
Chapel Hill, North Carolina, Stany Zjednoczone, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Clyde, North Carolina, Stany Zjednoczone, 28721
- AdventHealth Infusion Center Haywood
-
Durham, North Carolina, Stany Zjednoczone, 27710
- Duke University Medical Center
-
Goldsboro, North Carolina, Stany Zjednoczone, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Hendersonville, North Carolina, Stany Zjednoczone, 28791
- Margaret R Pardee Memorial Hospital
-
Hendersonville, North Carolina, Stany Zjednoczone, 28792
- AdventHealth Hendersonville
-
Jacksonville, North Carolina, Stany Zjednoczone, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
Pinehurst, North Carolina, Stany Zjednoczone, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Raleigh, North Carolina, Stany Zjednoczone, 27609
- Duke Cancer Center Raleigh
-
Wilmington, North Carolina, Stany Zjednoczone, 28401
- Novant Health New Hanover Regional Medical Center
-
Winston-Salem, North Carolina, Stany Zjednoczone, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Bismarck, North Dakota, Stany Zjednoczone, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Stany Zjednoczone, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Stany Zjednoczone, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Stany Zjednoczone, 44307
- Cleveland Clinic Akron General
-
Canton, Ohio, Stany Zjednoczone, 44710
- Aultman Health Foundation
-
Centerville, Ohio, Stany Zjednoczone, 45459
- Miami Valley Hospital South
-
Cincinnati, Ohio, Stany Zjednoczone, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cincinnati, Ohio, Stany Zjednoczone, 45220
- Good Samaritan Hospital - Cincinnati
-
Cincinnati, Ohio, Stany Zjednoczone, 45247
- TriHealth Cancer Institute-Westside
-
Cleveland, Ohio, Stany Zjednoczone, 44109
- MetroHealth Medical Center
-
Cleveland, Ohio, Stany Zjednoczone, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Stany Zjednoczone, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, Stany Zjednoczone, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Stany Zjednoczone, 43210
- Ohio State University Comprehensive Cancer Center
-
Columbus, Ohio, Stany Zjednoczone, 43219
- The Mark H Zangmeister Center
-
Dayton, Ohio, Stany Zjednoczone, 45405
- Grandview Hospital
-
Findlay, Ohio, Stany Zjednoczone, 45840
- Orion Cancer Care
-
Mayfield Heights, Ohio, Stany Zjednoczone, 44124
- Hillcrest Hospital Cancer Center
-
Sylvania, Ohio, Stany Zjednoczone, 43560
- ProMedica Flower Hospital
-
Toledo, Ohio, Stany Zjednoczone, 43606
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
West Chester, Ohio, Stany Zjednoczone, 45069
- University of Cincinnati Cancer Center-West Chester
-
Wright-Patterson Air Force Base, Ohio, Stany Zjednoczone, 45433
- Wright-Patterson Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stany Zjednoczone, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, Stany Zjednoczone, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
Tulsa, Oklahoma, Stany Zjednoczone, 74133
- Cancer Treatment Centers of America
-
-
Oregon
-
Bend, Oregon, Stany Zjednoczone, 97701
- Saint Charles Health System
-
Gresham, Oregon, Stany Zjednoczone, 97030
- Legacy Mount Hood Medical Center
-
Portland, Oregon, Stany Zjednoczone, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Tualatin, Oregon, Stany Zjednoczone, 97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Abington, Pennsylvania, Stany Zjednoczone, 19001
- Jefferson Abington Hospital
-
Bethlehem, Pennsylvania, Stany Zjednoczone, 18015
- Saint Luke's University Hospital-Bethlehem Campus
-
Bryn Mawr, Pennsylvania, Stany Zjednoczone, 19010
- Bryn Mawr Hospital
-
Danville, Pennsylvania, Stany Zjednoczone, 17822
- Geisinger Medical Center
-
Ephrata, Pennsylvania, Stany Zjednoczone, 17522
- Ephrata Cancer Center
-
Ephrata, Pennsylvania, Stany Zjednoczone, 17522
- Ephrata Community Hospital
-
Gettysburg, Pennsylvania, Stany Zjednoczone, 17325
- Adams Cancer Center
-
Hanover, Pennsylvania, Stany Zjednoczone, 17331
- WellSpan Medical Oncology and Hematology
-
Harrisburg, Pennsylvania, Stany Zjednoczone, 17109
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
-
Lebanon, Pennsylvania, Stany Zjednoczone, 17042
- Sechler Family Cancer Center
-
Lewisburg, Pennsylvania, Stany Zjednoczone, 17837
- Geisinger Medical Oncology-Lewisburg
-
Paoli, Pennsylvania, Stany Zjednoczone, 19301
- Paoli Memorial Hospital
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19104
- University of Pennsylvania/Abramson Cancer Center
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15224
- West Penn Hospital
-
Sayre, Pennsylvania, Stany Zjednoczone, 18840
- Guthrie Medical Group PC-Robert Packer Hospital
-
West Reading, Pennsylvania, Stany Zjednoczone, 19611
- Reading Hospital
-
Wexford, Pennsylvania, Stany Zjednoczone, 15090
- Wexford Health and Wellness Pavilion
-
Williamsport, Pennsylvania, Stany Zjednoczone, 17701
- UPMC Susquehanna
-
Willow Grove, Pennsylvania, Stany Zjednoczone, 19090
- Asplundh Cancer Pavilion
-
Wynnewood, Pennsylvania, Stany Zjednoczone, 19096
- Lankenau Medical Center
-
York, Pennsylvania, Stany Zjednoczone, 17403
- WellSpan Health-York Hospital
-
-
Rhode Island
-
Providence, Rhode Island, Stany Zjednoczone, 02905
- Women and Infants Hospital
-
-
South Carolina
-
Anderson, South Carolina, Stany Zjednoczone, 29621
- AnMed Health Cancer Center
-
Gaffney, South Carolina, Stany Zjednoczone, 29341
- Gibbs Cancer Center-Gaffney
-
Greenville, South Carolina, Stany Zjednoczone, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Stany Zjednoczone, 29601
- Saint Francis Hospital
-
Greer, South Carolina, Stany Zjednoczone, 29651
- Gibbs Cancer Center-Pelham
-
Hilton Head Island, South Carolina, Stany Zjednoczone, 29926-3827
- South Carolina Cancer Specialists PC
-
Spartanburg, South Carolina, Stany Zjednoczone, 29303
- Spartanburg Medical Center
-
Union, South Carolina, Stany Zjednoczone, 29379
- SMC Center for Hematology Oncology Union
-
-
South Dakota
-
Rapid City, South Dakota, Stany Zjednoczone, 57701
- Rapid City Regional Hospital
-
Sioux Falls, South Dakota, Stany Zjednoczone, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Stany Zjednoczone, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Stany Zjednoczone, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Kingsport, Tennessee, Stany Zjednoczone, 37660
- Ballad Health Cancer Care - Kingsport
-
Kingsport, Tennessee, Stany Zjednoczone, 37660
- Wellmont Holston Valley Hospital and Medical Center
-
Knoxville, Tennessee, Stany Zjednoczone, 37916
- Covenant Health Cancer Centers
-
Knoxville, Tennessee, Stany Zjednoczone, 37932
- Covenant Health Cancer Centers - West
-
Nashville, Tennessee, Stany Zjednoczone, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Dallas, Texas, Stany Zjednoczone, 75235
- Parkland Memorial Hospital
-
Dallas, Texas, Stany Zjednoczone, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Houston, Texas, Stany Zjednoczone, 77030
- Houston Methodist Hospital
-
Houston, Texas, Stany Zjednoczone, 77070
- Methodist Willowbrook Hospital
-
Sugar Land, Texas, Stany Zjednoczone, 77479
- Houston Methodist Sugar Land Hospital
-
-
Utah
-
Murray, Utah, Stany Zjednoczone, 84107
- Intermountain Medical Center
-
Salt Lake City, Utah, Stany Zjednoczone, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, Stany Zjednoczone, 84106
- Utah Cancer Specialists-Salt Lake City
-
South Jordan, Utah, Stany Zjednoczone, 84009
- South Jordan Health Center
-
St. George, Utah, Stany Zjednoczone, 84770
- Saint George Regional Medical Center
-
-
Vermont
-
Berlin Corners, Vermont, Stany Zjednoczone, 05602
- Central Vermont Medical Center/National Life Cancer Treatment
-
Burlington, Vermont, Stany Zjednoczone, 05401
- University of Vermont Medical Center
-
Burlington, Vermont, Stany Zjednoczone, 05405
- University of Vermont and State Agricultural College
-
-
Virginia
-
Charlottesville, Virginia, Stany Zjednoczone, 22908
- University of Virginia Cancer Center
-
Richmond, Virginia, Stany Zjednoczone, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Stany Zjednoczone, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Washington
-
Bellingham, Washington, Stany Zjednoczone, 98225
- PeaceHealth Saint Joseph Medical Center
-
Edmonds, Washington, Stany Zjednoczone, 98026
- Swedish Cancer Institute-Edmonds
-
Kennewick, Washington, Stany Zjednoczone, 99336
- Kadlec Clinic Hematology and Oncology
-
Mount Vernon, Washington, Stany Zjednoczone, 98274
- Skagit Valley Hospital
-
Mount Vernon, Washington, Stany Zjednoczone, 98274
- Skagit Regional Health Cancer Care Center
-
Seattle, Washington, Stany Zjednoczone, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Stany Zjednoczone, 98195
- University of Washington Medical Center - Montlake
-
Seattle, Washington, Stany Zjednoczone, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, Stany Zjednoczone, 98109
- Fred Hutchinson Cancer Center
-
Seattle, Washington, Stany Zjednoczone, 98133
- University of Washington Medical Center - Northwest
-
Seattle, Washington, Stany Zjednoczone, 98133
- Women's Cancer Center of Seattle
-
Vancouver, Washington, Stany Zjednoczone, 98686
- Legacy Salmon Creek Hospital
-
Wenatchee, Washington, Stany Zjednoczone, 98801
- Wenatchee Valley Hospital and Clinics
-
-
West Virginia
-
Charleston, West Virginia, Stany Zjednoczone, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
Huntington, West Virginia, Stany Zjednoczone, 25701
- Edwards Comprehensive Cancer Center
-
Morgantown, West Virginia, Stany Zjednoczone, 26506
- West Virginia University Healthcare
-
Morgantown, West Virginia, Stany Zjednoczone, 26505
- Monongalia Hospital
-
-
Wisconsin
-
Appleton, Wisconsin, Stany Zjednoczone, 54915
- Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton
-
Burlington, Wisconsin, Stany Zjednoczone, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Chippewa Falls, Wisconsin, Stany Zjednoczone, 54729
- Marshfield Clinic-Chippewa Center
-
Eau Claire, Wisconsin, Stany Zjednoczone, 54701
- Marshfield Clinic Cancer Center at Sacred Heart
-
Fond du Lac, Wisconsin, Stany Zjednoczone, 54937
- Aurora Health Center-Fond du Lac
-
Germantown, Wisconsin, Stany Zjednoczone, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Stany Zjednoczone, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Stany Zjednoczone, 54311
- Aurora BayCare Medical Center
-
Green Bay, Wisconsin, Stany Zjednoczone, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Green Bay, Wisconsin, Stany Zjednoczone, 54303
- Saint Vincent Hospital Cancer Center at Saint Mary's
-
Kenosha, Wisconsin, Stany Zjednoczone, 53142
- Aurora Cancer Care-Kenosha South
-
La Crosse, Wisconsin, Stany Zjednoczone, 54601
- Gundersen Lutheran Medical Center
-
Ladysmith, Wisconsin, Stany Zjednoczone, 54848
- Marshfield Medical Center - Ladysmith
-
Madison, Wisconsin, Stany Zjednoczone, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Marinette, Wisconsin, Stany Zjednoczone, 54143
- Aurora Bay Area Medical Group-Marinette
-
Marinette, Wisconsin, Stany Zjednoczone, 54143
- Saint Vincent Hospital Cancer Center at Marinette
-
Marshfield, Wisconsin, Stany Zjednoczone, 54449
- Marshfield Medical Center-Marshfield
-
Mequon, Wisconsin, Stany Zjednoczone, 53097
- Ascension Columbia Saint Mary's Hospital-Ozaukee Campus-Mequon
-
Milwaukee, Wisconsin, Stany Zjednoczone, 53226
- Medical College of Wisconsin
-
Milwaukee, Wisconsin, Stany Zjednoczone, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Stany Zjednoczone, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Stany Zjednoczone, 53233
- Aurora Sinai Medical Center
-
Milwaukee, Wisconsin, Stany Zjednoczone, 53211
- Ascension Columbia Saint Mary's Hospital-Milwaukee Campus
-
Minocqua, Wisconsin, Stany Zjednoczone, 54548
- Marshfield Medical Center - Minocqua
-
Mukwonago, Wisconsin, Stany Zjednoczone, 53149
- ProHealth D N Greenwald Center
-
Oconomowoc, Wisconsin, Stany Zjednoczone, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Oconto Falls, Wisconsin, Stany Zjednoczone, 54154
- Saint Vincent Hospital Cancer Center at Oconto Falls
-
Oshkosh, Wisconsin, Stany Zjednoczone, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Oshkosh, Wisconsin, Stany Zjednoczone, 54904
- Ascension Northeast Wisconsin-Mercy Hospital-Oshkosh
-
Racine, Wisconsin, Stany Zjednoczone, 53406
- Aurora Cancer Care-Racine
-
Rice Lake, Wisconsin, Stany Zjednoczone, 54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan, Wisconsin, Stany Zjednoczone, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Stevens Point, Wisconsin, Stany Zjednoczone, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Stevens Point, Wisconsin, Stany Zjednoczone, 54481
- Aspirus Cancer Care - Stevens Point
-
Sturgeon Bay, Wisconsin, Stany Zjednoczone, 54235-1495
- Saint Vincent Hospital Cancer Center at Sturgeon Bay
-
Summit, Wisconsin, Stany Zjednoczone, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, Stany Zjednoczone, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Waukesha, Wisconsin, Stany Zjednoczone, 53188
- UW Cancer Center at ProHealth Care
-
Waukesha, Wisconsin, Stany Zjednoczone, 53188
- ProHealth Waukesha Memorial Hospital
-
Wausau, Wisconsin, Stany Zjednoczone, 54401
- Marshfield Clinic-Wausau Center
-
Wauwatosa, Wisconsin, Stany Zjednoczone, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, Stany Zjednoczone, 53227
- Aurora West Allis Medical Center
-
Weston, Wisconsin, Stany Zjednoczone, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, Stany Zjednoczone, 54494
- Marshfield Clinic - Wisconsin Rapids Center
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
Patients must have histologically or cytologically confirmed ovarian cancer, peritoneal cancer or fallopian tube cancer and must have a histological diagnosis of either serous or endometrioid cancer based on local histopathological findings; both endometrioid and serous histology should be high-grade for eligibility of non-mutation carriers; patients with clear cell, mixed epithelial, undifferentiated carcinoma, or transitional cell carcinoma histologies are also eligible, provided that the patient has a known deleterious germline BRCA1 or BRCA2 mutation identified through testing at a clinical laboratory
- Note: Due to the long acceptance of BRCA testing through Myriad, Myriad testing will be accepted; if testing for BRCA is done by other organizations, documentation from a qualified medical professional (e.g., ovarian cancer specialty physician involved in the field, high risk genetics physician, genetics counselor) listing the mutation and confirming that the laboratory results showed a recognized germ line deleterious BRCA 1 or BRCA 2 mutation or BRCA rearrangement is required (12/05/2016); a copy of Myriad or other BRCA mutational analysis (positive or variants of unknown significance [VUS] or negative) reports will be requested but not required for study enrollment
-
Patients should have recurrent platinum-resistant or- refractory disease - defined as disease that has progressed by imaging while receiving platinum or had recurrence within 6 months of the last receipt of platinum-based chemotherapy; rising CA125 only is not considered as platinum-resistant or refractory disease (12/05/2016)
-
Phase II study: measurable disease by RECIST 1.1 criteria; if archival tumor sample is not available tumor sample from fresh biopsy is acceptable (12/05/2016)
-
Phase III study: evaluable disease - defined as RECIST 1.1 measurable disease OR non-measurable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease-related in the setting of a cancer antigen [CA]125 >= 2 x upper limit of normal [ULN])
-
No more than 3 prior treatment regimens (including primary therapy; no more than 1 prior non-platinum based therapy in the platinum-resistant/-refractory setting); hormonal therapies used as single agents (i.e. tamoxifen, aromatase inhibitors) will not count towards this line limit (12/05/2016)
-
Patients may not have had a prior anti-angiogenic agent in the recurrent setting; prior use of bevacizumab in the upfront or upfront maintenance setting is allowed
-
Patients may not have previously received a PARP-inhibitor
-
Patient must have provided study specific informed consent prior to study entry
-
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 or 2
-
Absolute neutrophil count >= 1,500/mcL (12/05/2016)
-
Platelets >= 100,000/mcL (12/05/2016)
-
Hemoglobin >= 10 g/dL (12/05/2016)
-
Total bilirubin within =< 1.5 times the upper limit of normal (ULN) institutional limits (12/05/2016)
-
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN; if intrahepatic liver metastases are present, AST and ALT must be =< 5 times institutional ULN (12/05/2016)
-
Creatinine =< 1.5 x the institutional ULN (12/05/2016)
-
Urine protein: creatinine ratio urine protein creatinine (UPC) of =< 1 OR less than or equal to 2+ proteinuria on two consecutive dipsticks taken no less than 1 week apart; UPC is the preferred test; patients with 2+ proteinuria on dipstick must also have a 24-hour urine collection demonstrating protein of =< 500 mg over 24 hours (12/05/2016)
-
Toxicities of prior therapy (excepting alopecia) should be resolved to less than or equal to grade 1 as per CTCAE; patients with long-standing stable grade 2 neuropathy may be considered after discussion with the study chair.
-
Adequately controlled blood pressure (systolic blood pressure [SBP] =< 140; diastolic blood pressure [DBP] =< 90 mmHg) on maximum of three antihypertensive medications; patients must have a BP of =< 140/90 mmHg taken in the clinic setting by a medical professional within 2 weeks prior to starting study; it is strongly recommended that patients who are on three antihypertensive medications be followed by a cardiologist or a primary care physician for management of BP while on protocol; patients must be willing and able to check and record daily blood pressure readings; blood pressure cuffs will be provided to patients randomized to cediranib alone and the combination of olaparib and cediranib arms (12/05/2016)
-
Adequately controlled thyroid function, with no symptoms of thyroid dysfunction and thyroid-stimulating hormone (TSH) within normal limits (12/05/2016)
-
Able to swallow and retain oral medications and without gastrointestinal (GI) illnesses that would preclude absorption of cediranib or olaparib
-
Age >= 18 years
-
Cediranib has been shown to terminate fetal development in the rat, as expected for a process dependent on VEGF signaling; for this reason, women of child-bearing potential must have a negative pregnancy test prior to study entry; women of child-bearing potential must agree to use two reliable forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 weeks after cediranib discontinuation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
-
Olaparib adversely affects embryofetal survival and development in the rat; for this reason, women of child-bearing potential must have a negative pregnancy test prior to study entry; women of child-bearing potential must agree to use must agree to use two reliable forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 3 months after the last dose of olaparib; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
Exclusion Criteria:
-
Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) of starting treatment or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; patients may not have had hormonal therapy within 2 weeks prior to entering the study; patients receiving raloxifene for bone health as per Food and Drug Administration (FDA) indication may remain on raloxifene absent other drug interactions (12/05/2016)
-
Any other investigational agents within the past 4 weeks
-
Prior treatment affecting the VEGF/VEGFR pathway or the angiopoietin pathway in the recurrent setting, including but not limited to thalidomide, bevacizumab, sunitinib, sorafenib, pazopanib, cediranib, nintedanib, and trebananib; bevacizumab used in the upfront setting in conjunction with chemotherapy and/or as maintenance to treat newly diagnosed disease will be allowed
-
Prior use of PARP-inhibitors
-
CA-125 only disease without Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measurable or otherwise evaluable disease
-
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to starting cediranib
-
Current signs and/or symptoms of bowel obstruction or signs and/or symptoms of bowel obstruction within 3 months prior to starting study drugs
-
History of intra-abdominal abscess within the past 3 months
-
History of gastrointestinal perforation; patients with a history of abdominal fistula will be considered eligible if the fistula was surgically repaired or has healed, there has been no evidence of fistula for at least 6 months, and patient is deemed to be at low risk of recurrent fistula (12/05/2016)
-
Dependency on IV hydration or total parenteral nutrition (TPN)
-
Any concomitant or prior invasive malignancies with the following curatively treated exceptions:
- Treated limited stage basal cell or squamous cell carcinoma of the skin
- Carcinoma in situ of the breast or cervix
- Primary endometrial cancer meeting the following conditions: stage not greater than IA, grade 1 or 2, no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous/serous, clear cell, or other Federation of Gynecology and Obstetrics (FIGO) grade 3 lesions (12/05/2016)
- Prior cancer treated with a curative intent with no evidence of recurrent disease 5 years following diagnosis and judged by the investigator to be at low risk of recurrence
-
Patients with untreated brain metastases, spinal cord compression, or evidence of symptomatic brain metastases or leptomeningeal disease as noted on computed tomography (CT) or magnetic resonance imaging (MRI) scans should not be included on this study, since neurologic dysfunction may confound the evaluation of neurologic and other adverse events; patients with treated brain metastases and resolution of any associated symptoms must demonstrate stable post-therapeutic imaging for at least 6 months following therapy prior to starting study drug
-
Patients with any of the following:
- History of myocardial infarction within six months
- Unstable angina
- Resting electrocardiogram (ECG) with clinically significant abnormal findings
- New York Heart Association functional classification of III or IV
-
If cardiac function assessment is clinically indicated or performed: left ventricular ejection fraction (LVEF) less than normal per institutional guidelines, or < 55%, if threshold for normal not otherwise specified by institutional guidelines
-
Patients with the following risk factors should have a baseline cardiac function assessment:
- Prior treatment with anthracyclines
- Prior treatment with trastuzumab
- Prior central thoracic radiation therapy (RT), including RT to the heart
- History of myocardial infarction within 6 to 12 months (Patients with history of myocardial infarction within 6 months are excluded from the study)
- Prior history of impaired cardiac function
-
-
History of stroke or transient ischemic attack within six months
-
Clinical significant peripheral vascular disease or vascular disease (aortic aneurysm or aortic dissection)
-
Evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted
-
Evidence suggestive of myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) on peripheral blood smear or bone marrow biopsy, if clinically indicated
- No prior allogeneic bone marrow transplant or double umbilical cord blood transplantation (dUBCT)
-
Patients may not use any complementary or alternative medicines including natural herbal products or folk remedies as they may interfere with the effectiveness of the study treatments
-
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia (other than atrial fibrillation with controlled ventricular rate), or psychiatric illness/social situations that would limit compliance with study requirements (12/05/2016)
-
Known human immunodeficiency virus (HIV)-positive individuals are ineligible because of the potential for pharmacokinetic interactions with cediranib or olaparib; in addition, these individuals are at increased risk of lethal infections when treated with marrow-suppressive therapy
-
Participants receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 are ineligible
- Strong inhibitors and inducers of UGT/PgP should be used with caution (12/05/2016)
-
Pregnant women are excluded from this study because cediranib and olaparib are agents with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with cediranib and olaparib, breastfeeding should be discontinued if the mother is treated with cediranib or olaparib; these potential risks may also apply to other agents used in this study
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Aktywny komparator: Phase II Arm I (reference regimen)
Patients undergo physician's choice of standard of care chemotherapy, comprising either paclitaxel IV over 60 minutes on days 1, 8, 15, and 22 every 28 days (Regimen I); pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 every 28 days (Regimen II); or topotecan hydrochloride IV over 30 minutes on days 1, 8, and 15 every 28 days or days 1-5 every 21 days (Regimen III). Treatment continues in the absence of disease progression or unacceptable toxicity. No modification of the assigned regimens, such as additional drugs (gemcitabine, or bevacizumab) is allowed. Patients also undergo CT and MRI throughout the study. (12/05/2016) |
Given IV
Inne nazwy:
Undergo CT
Inne nazwy:
Undergo MRI
Inne nazwy:
Ancillary studies Given IV
Inne nazwy:
Given IV
Inne nazwy:
Given IV
Inne nazwy:
|
|
Eksperymentalny: Phase II Arm II (cediranib maleate, olaparib)
Patients receive cediranib maleate PO QD and olaparib PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study. |
Undergo CT
Inne nazwy:
Undergo MRI
Inne nazwy:
Ancillary studies Given PO
Inne nazwy:
Given PO
Inne nazwy:
Given PO
Inne nazwy:
|
|
Eksperymentalny: Phase II Arm III (cediranib maleate)
Patients receive cediranib maleate PO daily continuously. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study. |
Undergo CT
Inne nazwy:
Undergo MRI
Inne nazwy:
Ancillary studies Given PO
Inne nazwy:
Given PO
Inne nazwy:
|
|
Eksperymentalny: Phase II Arm IV (olaparib)
Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study. (In July 2018, the Data Monitoring Committee voted to exclude the olaparib alone regimen). |
Undergo CT
Inne nazwy:
Undergo MRI
Inne nazwy:
Ancillary studies Given PO
Inne nazwy:
|
|
Aktywny komparator: Phase III Arm I (reference regimen)
Patients undergo physician's choice standard of care chemotherapy as in Phase II Arm I. No modification of the assigned regimens, such as additional drugs (gemcitabine or bevacizumab) is allowed. Patients also undergo CT and MRI throughout the study. (12/05/2016) |
Given IV
Inne nazwy:
Undergo CT
Inne nazwy:
Undergo MRI
Inne nazwy:
Ancillary studies Given IV
Inne nazwy:
Given IV
Inne nazwy:
Given IV
Inne nazwy:
|
|
Eksperymentalny: Phase III Arm II (cediranib maleate, olaparib)
Patients receive cediranib maleate PO and olaparib PO as in Phase II Arm II. Patients also undergo CT and MRI throughout the study. |
Undergo CT
Inne nazwy:
Undergo MRI
Inne nazwy:
Ancillary studies Given PO
Inne nazwy:
Given PO
Inne nazwy:
Given PO
Inne nazwy:
|
|
Eksperymentalny: Phase III Arm III (single-agent cediranib maleate)
Patients receive cediranib maleate PO as determined by the Phase II study. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and MRI throughout the study. |
Undergo CT
Inne nazwy:
Undergo MRI
Inne nazwy:
Ancillary studies Given PO
Inne nazwy:
Given PO
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Progression-free Survival (PFS) (Phase II Only)
Ramy czasowe: The protocol required lesion assessments every 9 weeks from cycle 1, day 1 for the first year, then every 12 weeks thereafter until disease progression. Approximately 42 months.
|
Progression free survival (PFS) was defined as the number of months between study enrollment and documentation of disease progression (RECIST 1.1) or death from any cause. Patients still alive and disease free at the last follow-up were censored on the date of last CT Scan, or the CT Scan date prior to two missed assessments. Disease progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
The protocol required lesion assessments every 9 weeks from cycle 1, day 1 for the first year, then every 12 weeks thereafter until disease progression. Approximately 42 months.
|
|
Progression-free Survival (PFS) (Phase III Only)
Ramy czasowe: The protocol required lesion assessments every 9 weeks from cycle 1, day 1 for the first year, then every 12 weeks thereafter until disease progression. Approximately 42 months.
|
Progression free survival (PFS) was defined as the number of months between study enrollment and documentation of disease progression (RECIST 1.1) or death from any cause. Patients still alive and disease free at the last follow-up were censored on the date of last CT Scan, or the CT Scan date prior to two missed assessments. Disease progression is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
The protocol required lesion assessments every 9 weeks from cycle 1, day 1 for the first year, then every 12 weeks thereafter until disease progression. Approximately 42 months.
|
|
Overall Survival (OS) (Phase III Only)
Ramy czasowe: Time from study enrollment to death due to any cause, assessed up to 5 years
|
Overall survival will be evaluated. To allow for better understanding of time to subsequent therapy and OS, patients on experimental study drug(s) or standard chemotherapy arm will be followed after progression, with data capture to include the date of initiation of the subsequent therapy, detailed information on the type of subsequent therapy received, and time to progression on the subsequent therapy. |
Time from study enrollment to death due to any cause, assessed up to 5 years
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Objective Response Rate (Complete Response and Partial Response) (Phase II Only)
Ramy czasowe: Up to 5 years
|
The Response Rates were estimated as the binomial proportion of patients with Best Overall Response of Complete or Partial response according to RECIST 1.1 criteria. A Complete response (CR) is defined as the complete disappearance of all target lesions, while a Partial response (PR) is defined as at least a 30% decrease in the sum of the longest diameters of target lesions compared to the baseline measurement; essentially, the tumor shrinks significantly but does not completely disappear. Overall response (OR) = CR + PR. |
Up to 5 years
|
|
Objective Response Rate (Complete Response and Partial Response for Phase III Only)
Ramy czasowe: Up to 5 years
|
The Response Rates were estimated as the binomial proportion of patients with Best Overall Response of Complete or Partial response according to RECIST 1.1 criteria. A Complete response (CR) is defined as the complete disappearance of all target lesions, while a Partial response (PR) is defined as at least a 30% decrease in the sum of the longest diameters of target lesions compared to the baseline measurement; essentially, the tumor shrinks significantly but does not completely disappear. Overall response (OR) = CR + PR. |
Up to 5 years
|
|
Incidence of Grade 3 (or Higher) Adverse Events
Ramy czasowe: Up to 5 years
|
Adverse events will be categorized by CTCAE V4.0. This outcome will report the count of participants who experienced a grade 3 (or higher) adverse event. |
Up to 5 years
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Patient-reported Scores of Disease-related Symptoms
Ramy czasowe: Up to 5 years
|
Measured by the 9-item Disease Related Symptoms (DRS-9) subscale of the National Comprehensive Cancer Network (NCCN)-Functional Assessment of Cancer Therapy (FACT) Ovarian Symptom Index (NFOSI-18). |
Up to 5 years
|
|
Gene Mutations Assessed BROCA-HR
Ramy czasowe: Up to 5 years
|
A single proportional hazards model will be used to estimate the treatment hazard ratios (and variances) for each of the experimental treatments selected for phase III evaluation relative to the reference treatment (chemotherapy) group. The model will include adjustments for prior platinum-free interval, prior bevacizumab treatment, age at study enrollment, randomly assigned study treatment and BROCA-HR status. The estimated hazard ratio(s) for BROCA-HR and the corresponding confidence intervals will be depicted with a forest plot, and assessed for qualitative interaction(s). |
Up to 5 years
|
|
Change in Circulating Endothelial Cell Levels
Ramy czasowe: Baseline up to 5 years
|
A proportional hazards model will be used to assess a linear association between the change in circulating endothelial cell values and the log relative hazard of death within each treatment group. Sensitivity analyses will include known prognostic factors in the model. A plot of the martingale residuals or estimated relative hazards by change in circulating endothelial cell quintiles will be used to qualitatively assess the assumption of a linear relationship between the change in circulating endothelial cell values and the log relative hazard. |
Baseline up to 5 years
|
|
Biomarkers in Plasma Angiome
Ramy czasowe: Up to 5 years
|
A proportional hazards model will be used to assess whether the pretreatment values of any of these analytes have a prognostic association with overall survival. The model will include clinical covariates: age, performance status, and the randomly assigned study treatment. Proportional hazards models will be used to assess the relationship between patients' analyte values and log hazard. A proportional hazards model will be used to assess the potential predictive associations between analytes, treatment and survival. |
Up to 5 years
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Jung-min Lee, NRG Oncology
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Szacowany)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Choroby układu moczowo-płciowego
- Choroby narządów płciowych
- Choroby układu hormonalnego
- Nowotwory układu moczowo-płciowego
- Nowotwory według lokalizacji
- Nowotwory
- Choroby układu moczowo-płciowego kobiet
- Choroby układu moczowo-płciowego kobiet i powikłania ciąży
- Choroby narządów płciowych, kobiety
- Nowotwory gruczołów dokrewnych
- Choroby jajników
- Choroby przydatków
- Nowotwory narządów płciowych, kobiety
- Zaburzenia gonad
- Choroby jajowodów
- Nowotwory jajnika
- Nowotwory jajowodu
- Organiczne chemikalia
- Związki heterocykliczne
- Techniki śledcze
- Węglowodory
- Cykloparafiny
- Węglowodory, Alicyklic
- Węglowodory, cykliczne
- Terpeny
- Węglowodany
- Campptothecin
- Alkaloidy
- Policykliczne aromatyczne węglowodory
- Węglowodory, aromatyczne
- Związki policykliczne
- Glikozydy
- Taksoidy
- Cyklodekan
- Diterpenes
- Ekonomia i organizacje opieki zdrowotnej
- Techniki chemii, analityczne
- Analiza widma
- Antracykliny
- Naftaceny
- Aminoglikozydy
- Daunorubicyna
- Ekonomika
- Doksorubicyna
- Paklitaksel
- Topotekan
- Spektroskopia rezonansu magnetycznego
- liposomalna doksorubicyna
- Olaparib
- Cediranib
- Podatki
Inne numery identyfikacyjne badania
- NCI-2015-00651
- U10CA180868 (Grant/umowa NIH USA)
- NCI-2015-00651 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
- NRG-GY005 (Inny identyfikator: CTEP)
- s16-01681
- NRG-GY005
- NRG-GY005 (Inny identyfikator: NRG Oncology)
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .